MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO
December 02, 2024 07:42 ET
|
MeAI
NEW YORK, NY, Dec. 02, 2024 (GLOBE NEWSWIRE) -- MeAI, a leading innovator in AI and DeSci, announces the listing of its native token, $MEAI, following a successful Initial Dex Offering (IDO). The...
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
July 19, 2024 07:55 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
June 28, 2024 07:55 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023 08:14 ET
|
SciSparc Ltd
The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder program TEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc...
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023 08:14 ET
|
Clearmind Medicine Inc.
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program Tel Aviv, Israel / Vancouver, Canada, Dec. 01, 2023 (GLOBE...
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 28, 2023 08:25 ET
|
SciSparc Ltd
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- ...
MeAI Unveils Solutions to Revolutionize Self-Improvement and Healthy Living with AI and Blockchain
October 10, 2023 11:55 ET
|
MeAI
NEW YORK, NY, Oct. 10, 2023 (GLOBE NEWSWIRE) -- MeAI is proud to annouce their solutions to revolutionize self-Improvement and healthy living with AI and Blockchain technology. In the...
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023 08:30 ET
|
SciSparc Ltd
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. ...
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
October 01, 2021 08:00 ET
|
Clearmind Medicine
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and...